BMEYE steps up expansion with €6m
This article was originally published in Clinica
Executive Summary
Dutch noninvasive cardiovascular monitoring company BMEYE is picking up the pace of its commercialisation activities following a €6m investment boost. The funds were raised in a series B round and came from new investors Earlybird and 360 Capital Partners, as well as from existing BMEYE shareholders Life Sciences Partners and Techfund. Amsterdam-based BMEYE has been selling its first product, Nexfin, in Europe and the US since the device was CE marked and FDA-cleared in 2007. The Nexfin uses a finger sensor to produce beat-to-beat, noninvasive blood pressure and cardiac output data. The company said it will use the series B financing to launch new products and expand its sales channels.